According to a study on phase III trial, that a fixed-dosing omadacycline strategy demonstrates consistent safety and efficacy in patients with community-acquired bacterial pneumonia or CABP, regardless of one’s body mass index or BMI.
 |
| Photo: Doctor Reading an X-Ray of Lungs | InStyleHealth |
There was a total of 756 patients hospitalized for
suspected CABP were randomized to receive intravenous omadacycline or moxifloxacin,
with an optional transition to oral, for 7 to 14 days. Of which, 278 patients
were of normal weight, 266 were overweight, and 212 were obese.
The clinical success rates 72-120 hours following
receipt of the first dose were similar in both treatment arms and across BMI
categories: 82.9%, 80.5%, and 76.9% normal weight, overweigh, and obese
patients in the omadacycline arm. Corresponding numbers in the moxifloxacin arm
were 88.6%, 80.7%, and 76.9%.
Outcomes were consistent in an analysis stratified by
diabetes status, with generally similar clinical success rates in the two treatment
groups. Patients who attained early clinical success or clinical stability generally
showed continued clinical success at 5-10 days after the last dose or
post-treatment evaluation.
The safety profiles of omadacycline and moxifloxacin
were largely comparable across BMI subgroups and by diabetes history.
Source: Respir Med 2021;184:106442